Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer.
Hiroshi KikuchiNako MaishiLi YuZi JiaCong LiMasumi SatoRyo TakedaKeita IshizukaYasuhiro HidaNobuo ShinoharaKyoko HidaPublished in: British journal of cancer (2023)
LDM CDDP does not cause inflammatory change unlike MTD CDDP, suggesting that it is a promising strategy in chemotherapy.